Searched for: subject:"Protein%5C%2BBinding"
(1 - 6 of 6)
document
Peeters, K.A.B.M. (author), Nordlee, J.A. (author), Penninks, A.H. (author), Chen, L. (author), Goodman, R.E. (author), Bruijnzeel-Koomen, C.A.F.M. (author), Hefle, S.L. (author), Taylor, S.L. (author), Knulst, A.C. (author), TNO Kwaliteit van Leven (author)
Background: Reports of lupine allergy are increasing as its use in food products increases. Lupine allergy might be the consequence of cross-reactivity after sensitization to peanut or other legumes or de novo sensitization. Lupine allergens have not been completely characterized. Objectives: We sought to identify allergens associated with...
article 2007
document
Albertini, R.J. (author), Anderson, D. (author), Douglas, G.R. (author), Hagmar, L. (author), Hemminki, K. (author), Merlo, F. (author), Natarajan, A.T. (author), Norppa, H. (author), Shuker, D.E.G. (author), Tice, R. (author), Waters, M.D. (author), Aitio, A. (author), TNO Kwaliteit van Leven TNO Bibra (author)
The purpose of these guidelines is to provide concise guidance on the planning, performing and interpretation of studies to monitor groups or individuals exposed to genotoxic agents. Most human carcinogens are genotoxic but not all genotoxic agents have been shown to be carcinogenic in humans. Although the main interest in these studies is due...
article 2000
document
Myrup, B. (author), Rossing, P. (author), Jensen, T. (author), Gram, J. (author), Kluft, C. (author), Jespersen, J. (author), Gaubius instituut TNO (author)
Objective: To investigate protein concentration changes during venous occlusion of proteins with reported affinity for extracellular matrix (plasminogen activator inhibitor type 1, antithrombin III, fibronectin and von Willebrand factor) in comparison with proteins with no reported affinity (albumin, tissue-type plasminogen activator,...
article 1999
document
de Jong, R.J. (author), Verwei, M. (author), West, C.E. (author), van Vliet, T. (author), Siebelink, E. (author), van den Berg, H. (author), Castenmiller, J.J.M. (author), TNO Kwaliteit van Leven (author)
Objective: The aim of this study was to investigate whether milk fortified with folic acid enhances the folate status of humans and whether the presence of folate-binding proteins (FBP) in pasteurised milk affects the bioavailability of folic acid from fortified milk. In untreated and pasteurised milk, folate occurs bound to FBP, while FBP is ...
article 2005
document
Rijken, D.C. (author), Barrett-Bergshoeff, M.M. (author), Jie, A.F.H. (author), Criscuoli, M. (author), Sakharov, D.V. (author), Gaubius Instituut TNO (author)
Amediplase (K2tu-PA) is a hybrid plasminogen activator, consisting of the kringle 2 domain of alteplase and the protease domain of urokinase. The objective of this study was to determine the in vitro clot penetration of amediplase in relation to its fibrin binding and to compare the properties with those of alteplase. The clot lysis activity of...
article 2004
document
Verwei, M. (author), van den Berg, H. (author), Havenaar, R. (author), Groten, J.P. (author), TNO Defensie en Veiligheid TNO Kwaliteit van Leven (author)
Background: Milk products are a potential matrix for fortification with synthetic folic acid or natural 5-methyltetrahydrofolate (5-CH 3-H4folate) to enhance the daily folate intake. In milk, folate occurs bound to folatebinding proteins (FBP). Our previous studies with an in vitro gastrointestinal model showed that 70% of the initial FBP...
article 2005
Searched for: subject:"Protein%5C%2BBinding"
(1 - 6 of 6)